Home > Newsletters > FDAnews Drug Daily Bulletin > As FDA Dawdles on Biosimilar Interchangeability, One Expert Questions Whether It’s Achievable
FDAnews Drug Daily Bulletin
Aug. 13, 2012 | Vol. 9 No. 158
As FDA Dawdles on Biosimilar Interchangeability, One Expert Questions Whether It’s Achievable
Companies blazing a path in the biosimilars arena likely have a long wait before their products can achieve an interchangeability designation, as the FDA admits to slow progress on that standard. And even after the standard is set, brand companies may have the only chance at getting an interchangeable designation, Jonathan Loeb, a partner at Dechert, said. Instead of developing products from scratch, they could create interchangeable versions of their own approved biologics, similar to how brand drugmakers create authorized generics.
Drug Industry Daily
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.